Teva Pharmaceutical Industries (TEVA) EBITDA (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported EBITDA for 18 consecutive years, with $652.0 million the latest figure, recorded in Q1 2026.

• Quarterly EBITDA rose 25.63% year-over-year to $652.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 427.42% YoY) and the FY2025 annual result came in at $2.2 billion, up 811.88% from the prior year.
• EBITDA improved to $652.0 million in Q1 2026 per TEVA's latest filing, from $300.0 million in the prior quarter.
• Over the last five years, EBITDA for TEVA reached as high as $882.0 million in Q3 2025 and fell as low as -$967.0 million in Q2 2022.
• A 5-year average of $43.6 million and a median of -$5.0 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2024 — EBITDA tumbled 1576.92% — and 2025, when it soared 9200.0%.
• Year by year, EBITDA stood at -$940.0 million in 2022, then jumped by 180.43% to $756.0 million in 2023, then tumbled by 103.84% to -$29.0 million in 2024, then jumped by 1134.48% to $300.0 million in 2025, then surged by 117.33% to $652.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $652.0 million, $300.0 million, and $882.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.